Please assess the completion status of the following clinical trial:

Trial Title: A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available~2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:~   * Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement~  * Neuroendocrine tumors~  * Solid tumors with tumor-induced pain~3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:~   * NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement~  * k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement~  * Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement~  * Pulmonary LCNEC;~4. Male or female ≥18 years of age~5. Eastern Cooperative Oncology Group performance status 0 to 1~6. Adequate organ function~7. Adequate blood clotting function~8. Women of childbearing potential must have a negative pregnancy test~9. Willingness to provide archival tumor samples~10. Other inclusion criteria may apply~Exclusion Criteria:~1. Hematological malignancies~2. Known positive HIV infection, or active hepatitis B or C infection~3. Comorbidity that would interfere with therapy~4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant~5. Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor~6. History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ≥2 according to NCI CTCAE, v4~7. Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement~8. Unresolved toxicities from previous anticancer therapy~9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment~10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment~11. Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment~12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein~13. Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption~14. QTcF values higher than 450 ms at screening~15. Breastfeeding~16. Other exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-6051b (Type: EXPERIMENTAL): DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.

Based on this trial design, predict the completion outcome and termination type (if applicable).